Health Care

Alnylam faces analyst downgrades amid a surge of RNA‑i start‑ups; its Q3 webcast will decide if it can retain lofty valuation or cede ground to rivals.

Hyperliquid Strategies (HYPE) surges as Ripple Prime expands to RWA swaps & perpetual futures, while a $100 M stake boosts stability—see how institutional moves shape HYPE’s future.

Intuitive Surgical’s CEO Patricia Wadors boosts her stake with new stock and RSUs, signaling strong confidence in the company’s future growth and innovation.

Explore Evaxion Biotech A/S: Danish biotech, Nasdaq‑listed, current market trends, valuation, challenges, and future growth prospects.

LivsMed Inc. leads Korea’s medical device market with advanced multi‑joint laparoscopic and vascular surgical instruments, boosting precision, efficiency, and patient recovery.

Fresenius Medical Care sees a boost: upgraded buy rating, higher €46 target, CFO extension, and board appointments set a rally narrative in a supportive European market.

FDA clears Anavex Life Sciences’ blarcamesine for first human trials in Fragile X syndrome, a breakthrough in precision genetic therapy for severe neurological disorders.

Personalis Inc.: Innovating personalized cancer vaccines amid volatile stock prices and a negative P/E, balancing breakthrough biotech research with investor risk.

Heidelberg Pharma cuts its 9‑month 2026 loss to €8.7 M, extends liquidity, and advances ADC oncology trials with new Chinese approval and a Huadong partnership.

ATAI Life Sciences, a Berlin‑based biopharma, pioneers psychedelic and non‑psychedelic drugs for depression, anxiety, PTSD, holding a $2.73B market cap and fueling hope for breakthrough mental health therapies.